Skip to main content
Clinical Trials/JPRN-UMIN000005442
JPRN-UMIN000005442
Completed
Phase 2

Clinical study to investigate the efficacy and the safety of R-FM for recurrent or refractory indolent B-cell lymphoma - THF016 - R-FM for recurrent or refractory indolent B-cell lymphoma

Tohoku Hematology Forum0 sites40 target enrollmentJune 1, 2011

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Tohoku Hematology Forum
Enrollment
40
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 1, 2011
End Date
August 1, 2015
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Tohoku Hematology Forum

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) active double cancer 2\) severe infection or severe complication 3\) having more than 300mg/m2 of Doxorubicin 4\) having prior Zevarin 5\) having prior purine analog 6\) having prior drug allergy 7\) prior treated heart failure or renal failure 8\) Cirrhosis of the liver 9\) HBs\-Ag positive 10\) Disorder of electrocardiogram, Disorder of heart fanction, severe heart disease 11\) pregnant/lactating woman 12\) psychosis 13\) given systemic steroid 14\) Physician's decision of inappropriateness

Outcomes

Primary Outcomes

Not specified

Similar Trials